Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tarafenacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 20/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 20/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tarafenacin SCHEMBL2278272 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Tarafenacin SCHEMBL2278264 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Tarafenacin SCHEMBL3751324 | 0.99 | CHRM3 (0.98) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Tarafenacin SCHEMBL3751328 | 0.99 | CHRM3 (0.98) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL13812723 | 0.94 | CHRM3 (0.88) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5006034 | 0.91 | CHRM1 (0.85) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5006033 | 0.91 | CHRM1 (0.85) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5006871 | 0.90 | CHRM2 (0.86) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5006110 | 0.90 | CHRM2 (0.90) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL5006869 | 0.90 | CHRM2 (0.86) | CHRM2CHRM1CHRM3CHRM5CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-12636447-B2 | Dry powder inhaler with an adherence/compliance monitor | VECTURA DELIVERY DEVICES LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| EP-3646870-B1 | COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | PureTech Health LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | disclosed |
| US-20260124147-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102381-A1 | Muscarinic Agent Combinations | Syremis Therapeutics, Ltd. (IL) | 2026-04-16 | — | — | US | disclosed |
| EP-3689332-B1 | FORMULATION COMPRISING GLYCOPYRROLATE, METHOD AND APPARATUS | VECTURA LTD (GB) | 2026-01-07 | — | — | EP | disclosed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250339418-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| EP-3981392-A1 | CONTROLLED RELEASE DOSAGE FORM | Triastek, Inc. (CN) | 2022-04-13 | — | — | EP | disclosed |
| US-20220105519-A1 | JET MILLING METHOD | VECTURA LIMITED (GB) | 2022-04-07 | — | — | US | disclosed |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | Triastek, Inc. (CN) | 2022-03-22 | — | — | US | disclosed |
| CN-108135851-B | Jet milling method | 维克多瑞有限公司 | 2022-03-15 | — | — | CN | disclosed |
| WO-2022043336-A1 | UNIT DOSE DRY POWDER INHALER | VECTURA DELIVERY DEVICES LIMITED (GB) | 2022-03-03 | — | — | WO | disclosed |
| US-20220054409-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2022-02-24 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| EP-3689339-B1 | JET MILLING METHOD | VECTURA LTD (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-11229915-B2 | Jet milling method | VECTURA LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | CYP2D6, CYP3A7, CYP3A5 | CHRM3 1706/4885CHRM2 1117/4885CHRM1 1387/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | CHRM3 4866/4885CHRM2 4861/4885CHRM1 4873/4885 |
| US-20260102381-A1 | Muscarinic Agent Combinations | CHRM1, CHRM4, CHRM2 | CHRM3 4/4885CHRM2 3/4885CHRM1 1/4885 |
| US-20250339418-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 8/4885 |
| US-20260124147-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM5, CHRM4, CHRM2 | CHRM3 4/4885CHRM2 3/4885CHRM1 11/4885 |
| US-12636447-B2 | Dry powder inhaler with an adherence/compliance monitor | CHRM2, CHRM1, CHRM4 | CHRM3 5/4885CHRM2 1/4885CHRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.